Find Clinical Trial

Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os) and rosiglitazone (4 to 8 mg daily per os) given in combination with metformin in type 2 diabetic patients.A 2-year international, multicentre, randomised, double-blind, parallel-group study followed by a 2-year double blind extension. – ENDORSE


← Back
Study Phase

Phase 3

Therapeutic Area

Metabolism

IndicationDiabetes - Type II
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

GLICLAZIDE,
S005702

Active Substance CodeS005702
Protocol CodeCL3-05702-013
EudraCT Code2006-001240-30
ISRCTN CodeISRCTN67790431


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility